Positive Phase 3 clinical data of Zai Lab's niraparib in first-line maintenance treatment of ovarian cancer patients in China
Time of Update: 2022-04-25
Transfer from | Medicine Guanlan>On March 21, Zai Lab announced that it had reported detailed data from the PRIME Phase 3 clinical study of niraparib
Zai Lab Qingle second-line treatment of gastrointestinal stromal tumor phase 3 clinical failure
Time of Update: 2021-12-08
Recently, Zai Lab's partner Deciphera announced the targeted anticancer drug Qinlock (Chinese product name: Qingle®, generic name: ripretinib, Ripetinib) for the second-line treatment of gastrointestinal stromal tumor (GIST) INTRIGUE Phase 3 clinical trial Top-line results of the study .
Zai Lab's Nirapali ovarian cancer first-line maintenance treatment indication approved in Hong Kong, China
Time of Update: 2021-09-20
Unlike other PARP inhibitors that have been approved in Hong Kong, Zele® does not require BRCA mutation or other biomarker testing before medication .
First in class gastric cancer first-line therapy won CDE plans to break through treatment Zai Lab owns Chinese rights
Time of Update: 2021-09-12
, Zai Lab and Five Prime reached an agreement to obtain the exclusive license right to develop and commercialize bemarituzumab in Greater China for US$44 million . In April of the same year
First-line treatment of gastric cancer, Zai Lab introduces new monoclonal antibody to treat breakthrough treatment
Time of Update: 2021-09-12
of FGFR2b overexpression and HER2-negative locally advanced/metastatic gastric and gastroesophageal junction cancer (G&GEJ) . > This product is a product that Zai Lab introduced from
ASCO's innovative first-line treatment for gastric cancer reduces the risk of death by 40%, Zai Lab owns rights in Greater China
Time of Update: 2021-06-18
5 months, the median overall survival (OS) of patients with FGFR2b positive and HER2-negative gastric cancer or gastroesophageal junction cancer (GEJ) who received bemarituzumab and chemotherapy first-line treatment was 19.
Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal...
Time of Update: 2021-05-03
>In June 2018, CStone Pharmaceuticals reached an exclusive cooperation and licensing agreement with Blueprint Medicines, and obtained the clinical development of the latter's avapritinib, BLU-554 and BLU-667 single-drug or combination therapy
Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal stromal tumors soon
Time of Update: 2021-04-27
(including PDGFRα D842V mutations) Adult patients with intestinal stromal tumor (GIST). In June 2018, CStone Pharmaceuticals reached an exclusive cooperation and licensing agreement with Blueprint Medicines, and obtained the clinical
Express | Innovative first-line therapy for gastric cancer is recognized as a breakthrough therapy by FDA, Zai Lab owns rights in Greater China
Time of Update: 2021-04-23
bemarituzumab, for approximately US$1. 9 billion. Zai Lab has previously reached a cooperation agreement with Five Prime to obtain the development rights of this innovative therapy in Greater China
Amgen received nearly US$2 billion in innovative first-line treatments for gastric cancer, Zai Lab owns rights in Greater China
Time of Update: 2021-03-23
In January this year, the US FDA accelerated the approval of the HER2 targeting antibody conjugate drug Enhertu jointly developed by AstraZeneca and Daiichi Sankyo to expand the scope of application to treat HER2-positive locally advanced or metastatic gastric cancer.